News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ambry Genetics Launches BRCA1/2: Single Genes and NGS Panel Offerings



6/14/2013 10:20:06 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics announced today the launch of BRCA1 and BRCA2 analysis as part of their comprehensive cancer-testing menu. Two genes will be offered as a stand alone test comprising of full gene sequencing and deletion/duplication analyses in addition to being incorporated as part of multiple hereditary cancer panels that test cancer susceptibility genes using next-generation sequencing (NGS) technology. Additionally, Ambry Genetics is excited to launch a new high-risk hereditary breast cancer panel (BRCAplus) that simultaneously analyzes six clinically actionable genes: BRCA1, BRCA2, CDH1, PTEN, STK11 and TP53. These additions complement Ambry’s comprehensive menu of single gene offerings and NGS multi-gene panels designed for hereditary cancer syndromes.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES